2026-04-22T22:13:07Zhttps://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/653442025-03-26T19:10:17Zcom_10324_1138com_10324_931com_10324_894col_10324_1922
Diebold Luque, María Yolanda
García Posadas, Laura
López Paniagua, Marina
De La Mata Sampedro, Ana
Galindo de la Rosa, Sara
Blázquez, Francisco
Calonge, Margarita
Nieto Miguel, Teresa
Herreras Cantalapiedra, José María
Coco Martín, Rosa María
Pastor Idoate, Salvador
Pastor Jimeno, José Carlos
Bhattarchajee, Promita
Ahearne, Mark
Nagai, Noriaki
Sakurai, Shunsuke
Seiriki, Ryotaro
Minami, Misa
Yamaguchi, Mizuki
Deguchi, Saori
Harata, Eiji
Ruíz Alonso, Sandra
Villate Beitia, Ilia
Lafuente Merchan, Markel
Puras, Gustavo
Saenz del Burgo, Laura
Pedraz, Jose Luis
Bosworth, Lucy A
Doherty, Kyle G
Hsuan, James D
Cray, Samuel P
D'Sa, Raechelle A
Pineda Molina, Catalina
Badylak, Stephen F
Williams, Rachel L
Mirazul Islam, Mohamed
AbuSamra, Dina B
Chivu, Alexandru
Argüeso, Pablo
Dohlman, Claes H
Patra, Hirak K
Chodosh, James
González Andrades, Miguel
Sánchez Porras, David
Caro Magdaleno, Manuel
González Gallardo, Carmen
García García, Oscar Darío
Garzón, Ingrid
Carriel, Victor
Campos, Fernando
Alaminos, Miguel
MDPI
2024-01-30T13:24:25Z
2024-01-30T13:24:25Z
2021
Diebold, Yolanda; García Posadas, Laura (eds.). Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges. Colección: Pharmaceutics, vol. 13. MDPI, 2021, 224 p.
978-3-0365-2610-2
https://uvadoc.uva.es/handle/10324/65344
10.3390/books978-3-0365-2610-2
Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges
Producción Científica
The concept of advanced therapy medicinal products (ATMPs) encompasses novel kinds of medicines for human use that are based on genes, cells or tissues. These intend to offer not only regeneration, but complete functional recovery of diseased tissues and organs using different strategies. Gene therapy, cell therapy and tissue engineering are the main areas in which promising advanced therapies are emerging. The eye is a very complex organ whose main structures, the
cornea and the retina, play a pivotal role in maintaining normal vision, as severe alterations in these tissues can lead to blindness. Ocular tissues are starting to benefit from ATMPs by fighting against the enormous complexity and devastating potential of many ocular diseases. However, developments arising from this field of work face important challenges related to vectors to deliver drugs and genetic material to target tissues, suitable biomaterials to prepare cell scaffolds and cell stemness, among others—not to mention the complicated legislation around ATMPs, the complexity in production and quality control and the absence of standardized protocols. The purpose of this Special Issue is to serve as an overview of the current progress in the application of cell and gene therapies, as well as tissue engineering to restore functionality in diseased ocular structures, and the challenges they deal with in order to get to patients.
Ministerio de Economía y Competitividad e Instituto de Salud Carlos III - FEDER (FIS PI20/0317 e ICI21-00010)
Junta de Andalucía - Consejería de Salud y Familias (PI-0086-2020)
Junta de Andalucía - Consejería de Transformación Económica, Industria, Conocimiento y Universidades- FEDER (B-CTS-504-UGR20)
application/pdf
eng
Pharmaceutics, volume 13
https://www.mdpi.com/books/book/4746
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2021 The Authors
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oftalmología
Advanced Therapy Medicinal Products (ATMPs)
Ocular diseases
Medicamentos de Terapia Avanzada (ATMP)
Enfermedades oculares
3201.09 Oftalmología
Advanced therapy medicinal products for eye diseases: Goals and challenges
info:eu-repo/semantics/book
info:eu-repo/semantics/publishedVersion